Lyndsay A Avalos1, Jeannette Ferber2, Ousseny Zerbo2, Allison L Naleway3, Joanna Bulkley3, Mark Thompson4, Janet Cragan5, Jennifer Williams5, Roxana Odouli2, Tia L Kauffman3, Sarah Ball6, Pat Shifflett6, De-Kun Li2. 1. Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. Electronic address: Lyndsay.A.Avalos@kp.org. 2. Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States. 3. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States. 4. Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. Abt Associates, Cambridge, MA, United States.
Abstract
OBJECTIVE: Despite recommendations by professional organizations that all pregnant women receive inactivated influenza vaccine, safety concerns remain a barrier. Our objective was to assess the effect of trivalent influenza vaccines (IIV3) during pregnancy on parent report 6-month infant development. METHODS: We conducted a multi-site prospective birth cohort study during the 2010-2011 influenza season and followed pregnant women and their newborns through 6 months of age. Information on IIV3 during pregnancy was ascertained from the EHR and self-report. The Ages and Stages Questionnaire-3 (ASQ-3) was completed by the mother to assess 6-month infant neurodevelopment in five domains (communication, gross motor, fine motor, problem-solving, and personal adaptive skills). Scores for each domain above the cut-off point indicating typical development were categorized as "on schedule" while scores in the zones indicating the need for either monitoring or further assessment were categorized as "not on schedule". Multivariable logistic regression was conducted. RESULTS: Of the 1225 infant-mother pairs, 65% received IIV3 during pregnancy. In bivariate analysis, infants of women who received IIV3 during pregnancy were moderately-less likely to need monitoring or further assessment in the personal social domain compared with infants of unvaccinated women (10.0% vs. 14.1%, p = 0.033; crude OR (cOR): 0.68(95%CI:0.48,0.97)). However, after controlling for potential confounders, the findings were no longer statistically significant (aOR:0.72,95%CI: 0.49,1.06,p = 0.46). No significant unadjusted or adjusted associations emerged in any other ASQ-3 domain. CONCLUSION: There was no significant association between IIV3 exposure during pregnancy and 6-month infant development. Studies of IIV3 during pregnancy to assess longer-term developmental outcomes are indicated.
OBJECTIVE: Despite recommendations by professional organizations that all pregnant women receive inactivated influenza vaccine, safety concerns remain a barrier. Our objective was to assess the effect of trivalent influenza vaccines (IIV3) during pregnancy on parent report 6-month infant development. METHODS: We conducted a multi-site prospective birth cohort study during the 2010-2011 influenza season and followed pregnant women and their newborns through 6 months of age. Information on IIV3 during pregnancy was ascertained from the EHR and self-report. The Ages and Stages Questionnaire-3 (ASQ-3) was completed by the mother to assess 6-month infant neurodevelopment in five domains (communication, gross motor, fine motor, problem-solving, and personal adaptive skills). Scores for each domain above the cut-off point indicating typical development were categorized as "on schedule" while scores in the zones indicating the need for either monitoring or further assessment were categorized as "not on schedule". Multivariable logistic regression was conducted. RESULTS: Of the 1225 infant-mother pairs, 65% received IIV3 during pregnancy. In bivariate analysis, infants of women who received IIV3 during pregnancy were moderately-less likely to need monitoring or further assessment in the personal social domain compared with infants of unvaccinated women (10.0% vs. 14.1%, p = 0.033; crude OR (cOR): 0.68(95%CI:0.48,0.97)). However, after controlling for potential confounders, the findings were no longer statistically significant (aOR:0.72,95%CI: 0.49,1.06,p = 0.46). No significant unadjusted or adjusted associations emerged in any other ASQ-3 domain. CONCLUSION: There was no significant association between IIV3 exposure during pregnancy and 6-month infant development. Studies of IIV3 during pregnancy to assess longer-term developmental outcomes are indicated.
Authors: Melissa D Bauman; Ana-Maria Iosif; Stephen E P Smith; Catherine Bregere; David G Amaral; Paul H Patterson Journal: Biol Psychiatry Date: 2013-09-05 Impact factor: 13.382
Authors: S H Fatemi; E S Emamian; D Kist; R W Sidwell; K Nakajima; P Akhter; A Shier; S Sheikh; K Bailey Journal: Mol Psychiatry Date: 1999-03 Impact factor: 15.992
Authors: Mark C Steinhoff; Saad B Omer; Eliza Roy; Shams El Arifeen; Rubhana Raqib; Caitlin Dodd; Robert F Breiman; K Zaman Journal: CMAJ Date: 2012-02-21 Impact factor: 8.262
Authors: Allison L Naleway; Stephanie A Irving; Michelle L Henninger; De-Kun Li; Pat Shifflett; Sarah Ball; Jennifer L Williams; Janet Cragan; Julianne Gee; Mark G Thompson Journal: Vaccine Date: 2014-04-14 Impact factor: 3.641
Authors: Paula E Goines; Lisa A Croen; Daniel Braunschweig; Cathleen K Yoshida; Judith Grether; Robin Hansen; Martin Kharrazi; Paul Ashwood; Judy Van de Water Journal: Mol Autism Date: 2011-08-02 Impact factor: 7.509
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan Journal: MMWR Recomm Rep Date: 2018-08-24